- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Triptans and Ischemic Events: A New Study Parses the Risk
Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.
All triptan medications, used for the management of migraine headaches, carry an FDA warning about potential risk for ischemic events including myocardial infarctions (MI) and stroke, however there are questions about whether this warning is more theoretical than based in reality.
The triptans are vasoconstrictors* and therefore it would appear logical that they would carry a risk for these adverse events. Many studies on the relationship, however, have failed to identify such an association.
A recent study approached the question by determining the frequency of ischemic events after initial treatment with a triptan.
*Although the antimigraine effects of triptans are often attributed to this vasoconstrictive effect, the exact mechanism responsible for effects of the drugs on migraine symptoms is still not completely understood.
Source: Petersen CL, Hougaard A, Gaist D, et al. Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol. Published online February 5, 2024. doi:10:1001/jamaneurol.2023.5549.
The CMS CED Policy Limits Treatment for Early Alzheimer's Disease: What It Is and How It Works
December 16th 2024The coverage with evidence development (CED) policy requires enrollment in an active clinical trial for an adult to be eligible for Medicare coverage of treatment for Alzheimer's disease.
